Gubra (GUBRA) Aandelenoverzicht
Gubra A/S, een biotechbedrijf, richt zich op preklinisch contractonderzoek en het ontdekken van peptiden voor metabolische en fibrotische ziekten in Europa, Noord-Amerika en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
GUBRA Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Gubra A/S Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | DKK 369.20 |
| 52 Week Hoogtepunt | DKK 571.00 |
| 52 Week Laag | DKK 293.00 |
| Bèta | 0.27 |
| 1 maand verandering | 9.30% |
| 3 maanden verandering | 0.11% |
| 1 Jaar Verandering | -33.30% |
| 3 jaar verandering | 301.30% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | 235.64% |
Recent nieuws en updates
GUBRA: Phase 2 Obesity Candidate Progress Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions. What's in the News Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, an investigational triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases.GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.Analysts' Revenue Estimates For Gubra A/S (CPH:GUBRA) Are Surging Higher
Gubra A/S ( CPH:GUBRA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...Recent updates
GUBRA: Phase 2 Obesity Candidate Progress Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions. What's in the News Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, an investigational triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases.GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.Analysts' Revenue Estimates For Gubra A/S (CPH:GUBRA) Are Surging Higher
Gubra A/S ( CPH:GUBRA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside
Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential
Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.GUBRA: Future Pipeline Milestones And Royalties Will Drive Upside Potential
Analysts have reduced their price target for Gubra from DKK 502.50 to DKK 469.50, reflecting updated views on discount rates, revenue contraction, profit margins and a significantly lower future P/E multiple. What's in the News Gubra plans an Analyst and Investor Day event, giving the market a closer look at its business model, pipeline and long term priorities (Key Developments).AbbVie Agreement And Clinical Trials Will Unlock New Avenues
The significant downward revision in Gubra’s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540. What's in the News Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors
Gubra A/S ( CPH:GUBRA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...AbbVie Agreement And Clinical Trials Will Unlock New Avenues
Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Gubra A/S ( CPH:GUBRA ) shareholders that were waiting for something to happen have been dealt a blow with a 26% share...We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up
Gubra A/S ( CPH:GUBRA ) shareholders would be excited to see that the share price has had a great month, posting a 25...Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%
Despite an already strong run, Gubra A/S ( CPH:GUBRA ) shares have been powering on, with a gain of 60% in the last...Rendement voor aandeelhouders
| GUBRA | DK Life Sciences | DK Markt | |
|---|---|---|---|
| 7D | 3.9% | -2.9% | -0.02% |
| 1Y | -33.3% | -10.6% | -22.4% |
Rendement versus industrie: GUBRA presteerde slechter dan de Danish Life Sciences -sector, die het afgelopen jaar een rendement van -10.6 % opleverde.
Rendement versus markt: GUBRA presteerde slechter dan Danish Market, dat het afgelopen jaar een rendement van -22.4 % opleverde.
Prijsvolatiliteit
| GUBRA volatility | |
|---|---|
| GUBRA Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 7.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DK Market | 8.5% |
| 10% least volatile stocks in DK Market | 2.8% |
Stabiele aandelenkoers: De aandelenkoers van GUBRA is de afgelopen 3 maanden volatiel geweest in vergelijking met de Danish markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van GUBRA is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Danish.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2008 | 300 | Markus Rohrwild | www.gubra.dk |
Gubra A/S, een biotechbedrijf, richt zich op preklinisch contractonderzoek en het ontdekken van peptiden voor metabolische en fibrotische ziekten in Europa, Noord-Amerika en internationaal. Het bedrijf is actief in drie segmenten: Preklinisch contractonderzoek (CRO), Discovery & Partnerships en Gubra Green. Het bedrijf biedt preklinisch contractonderzoek en ontwikkelingsdiensten aan op het gebied van metabolische en fibrotische ziekten voor de farmaceutische en biotechnologische industrie, evenals diensten op het gebied van in vivo farmacologie, biomarker assays, bioinformatica, next gen sequencing, farmacokinetiek en 2D en 3D histologie met kunstmatige intelligentie pathologie.
Gubra A/S Samenvatting
| GUBRA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | DKK 6.03b |
| Inkomsten(TTM) | DKK 1.69b |
| Inkomsten(TTM) | DKK 2.64b |
Is GUBRA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| GUBRA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | DKK 2.64b |
| Kosten van inkomsten | DKK 80.08m |
| Brutowinst | DKK 2.56b |
| Overige uitgaven | DKK 866.16m |
| Inkomsten | DKK 1.69b |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
Aug 20, 2026
| Winst per aandeel (EPS) | 103.51 |
| Brutomarge | 96.96% |
| Nettowinstmarge | 64.11% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde GUBRA op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/11 16:11 |
| Aandelenkoers aan het einde van de dag | 2026/06/11 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Gubra A/S wordt gevolgd door 3 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Rune Dahl | DNB Carnegie |
| Jesper Ilsøe | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |